CCCC

2.5052.66%
RH

Ronald H. W. Cooper

Independent Chairman

Mr. Ronald H. W. Cooper, also known as Ron, is Chief Executive Officer & Director of enGene Therapeutics Inc. (formerly known as enGene Holdings Inc.) from July 22, 2024 and serves as its President since October 21, 2024. Mr. Cooper is Independent Director and Chairman of C4 Therapeutics, Inc. from June 7, 2024. He served as Independent Director at Generation Bio Co. since March 2021 until February 09, 2026. He served as the Chief Executive Officer and President of Albireo Pharma Inc. since July 2015. He served as president and chief executive officer of Albireo Limited from July 2015 until November 2016 and also served as a member of the board of directors of Albireo Limited from September 2015 to November 2016. Mr. Cooper had a career at Bristol-Myers Squibb, where he worked in five different countries and held positions of increasing responsibility in sales, marketing and general management, culminating as President of Europe. He has successfully completed more than a dozen business development transactions, including the creation of the first single tablet HIV/AIDS regimen Partnership. Mr. Cooper had been Director of Albireo Pharma Inc. since September 2015 until March 01, 2023. Most recently, at Bristol-Myers Squibb Company, Mr. Cooper served as President, Europe from May 2010 until November 2015; President, Northern and Central Europe from April 2009 until April 2010; and Senior Vice President and General Manager, EU Markets from January 2008 until March 2009. He had been an Independent Director of Genocea Biosciences, Inc. since June 9, 2016 until April 12, 2021. Mr. Cooper earned his bachelor’s degree in Chemistry and Business Administration from St. Francis Xavier University in Canada.

Positions